Results 31 to 40 of about 12,617 (217)

Small-molecule factor D inhibitors selectively block the alternative pathway of complement in paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome

Haematologica, 2017
Paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome are diseases of excess activation of the alternative pathway of complement that are treated with eculizumab, a humanized monoclonal antibody against the terminal complement ...
Xuan Yuan, Eleni Gavriilaki, Jane A. Thanassi, Guangwei Yang, Andrea C. Baines, Steven D. Podos, Yongqing Huang, Mingjun Huang, Robert A. Brodsky   +8 more
doaj   +1 more source

Hemolytic uremic syndrome (HUS) – case report

Journal of Education, Health and Sport, 2020
Introduction Hemolytic uremic syndrome (HUS) is characterized by hemolytic anemia, thrombocytopenia and acute renal failure. In 90% of children, HUS most often develops after an intestinal infection caused by verotoxin-producing E. coli. The remaining 10%
Aleksandra Borkowska, Anna Sobstyl, Aleksandra Chałupnik, Zuzanna Chilimoniuk, Maciej Dobosz, Szymon Marosz   +5 more
doaj   +1 more source

Atypical hemolytic-uremic syndrome in children

Инновационная медицина Кубани, 2022
Background: Atypical hemolytic-uremic syndrome (aHUS) is a rare progressive form of systemic thrombotic microangiopathy (TMA), which develops due to uncontrolled activation of the alternative pathway of the complement system and is characterized by a ...
A. V. Burlutskaya, A. V. Statova, D. V. Ustyuzhaninа, Yu. V. Pisotskaya   +3 more
doaj   +1 more source

Two patients with history of STEC-HUS, posttransplant recurrence and complement gene mutations [PDF]

, 2013
Hemolytic uremic syndrome (HUS) is a disease of microangiopathic hemolytic anemia, thrombocytopenia and acute renal failure. About 90% of cases are secondary to infections by Escherichia coli strains producing Shiga-like toxins (STEC-HUS), while 10% are ...
Alberti, M., Bresin, E., Galbusera, M., Noris, M., Piras, R., Remuzzi, G., Thaiss, F., TRIPODO, Claudio, Valoti, E.   +8 more
core   +1 more source

Infection frequently triggers thrombotic microangiopathy in patients with preexisting risk factors : a single-institution experience [PDF]

, 2010
Thrombotic microangiopathies are rare conditions characterized by microangiopathic hemolytic anemia, microthrombi, and multiorgan insult. The disorders, which include hemolytic uremic syndrome and thrombotic thrombocytopenic purpura, are often acute and ...
Catlow, Jamie, Douglas, Kenneth W., Green, Rachel, Pollock, Kevin G.J., Young, David   +4 more
core   +1 more source

HUS and atypical HUS [PDF]

, 2017
Hemolytic uremic syndrome (HUS) is a thrombotic microangiopathy characterized by intravascular hemolysis, thrombocytopenia, and acute kidney failure. HUS is usually categorized as typical, caused by Shiga toxin-producing Escherichia coli (STEC) infection,
Al-Nouri, Allen, Amaral, Ardissino, Arvidsson, Atefi, Atkinson, Berry, Bhakdi, Bhattacharjee, Boltax, Brady, Bresin, Bruneau, Bu, Caires, Campistol, Canalejo, Carson, Chapin, Chien, Cofiell, Cole, Conway, Conway, Coppo, Cornec-Le Gall, de Córdoba, Del Conde, Delvaeye, Dempsey, Devine, Dhakal, Dragon-Durey, Egbor, El-Husseini, Faguer, Fakhouri, Ferreira, Ferreira, Fremeaux-Bacchi, Frimat, George, Gilbert, Gorsuch, Gottschalk, Grabowski, Greenbaum, Hill, Hornung, Hosler, Huber-Lang, Hughson, Hyvärinen, Iida, Ikeda, Jin, Jokiranta, Kang, Karnchanaphanurach, Karpman, Karpman, Karpman, Kavanagh, Keir, Kielstein, Kim, Kourouklaris, Krisinger, Kronbichler, Laurence, Law, Lechner, Lehtinen, Lemaire, Licht, Liszewski, Loirat, Lupu, Manuelian, Martel, Mathew, Matsukuma, Mele, Meri, Morton, Moskovich, Mukhopadhyay, Nakakuma, Nester, Noris, Noris, Noris, Oikonomopoulou, Orth-Höller, Ozaki, Pangburn, Pangburn, Pape, Pecoraro, Pilzer, Podack, Ricklin, Rinder, Rodríguez-Pintó, Roumenina, Ruggenenti, Schutte, Scully, Sethi, Sims, Sinha, Song, Ståhl, Ståhl, Sung, Szilágyi, T. Sakari Jokiranta, Tawadrous, Tedesco, Thomas, Thurman, Toh, Tsai, Tufano, Vasu, Ward, Warwicker, Wehling, Wetsel, Whaley, Wiedmer, Wig, Woodworth, Zipfel, Zipfel   +135 more
core   +1 more source

Case Series of 3 Patients Diagnosed With Atypical Hemolytic Uremic Syndrome Successfully Treated With Steroids, Plasmapheresis, and Rituximab

Canadian Journal of Kidney Health and Disease, 2017
Rationale: Atypical hemolytic uremic syndrome, which has a high probability of chronic kidney disease, morbidity, and mortality, needs to be promptly recognized when patients present with microangiopathic hemolysis.
Jeffery M. Patterson, Lauren Bolster, Loree Larratt   +2 more
doaj   +1 more source

Successful use of eculizumab to treat atypical hemolytic uremic syndrome in patients with inflammatory bowel disease

Thrombosis Journal, 2019
Background Atypical hemolytic uremic syndrome is a rare group of disorders that have in common underlying complement amplifying conditions. These conditions can accelerate complement activation that results in a positive feedback cycle.
Ramy M. Hanna, Noah Merin, Richard M. Burwick, Lama Abdelnour, Umut Selamet, Beshoy Yanny, Patrick Bui, Mary Fouad, Ira Kurtz   +8 more
doaj   +1 more source

Genetics of Atypical Hemolytic Uremic Syndrome (aHUS) [PDF]

Seminars in Thrombosis and Hemostasis, 2014
Hemolytic uremic syndrome (HUS) is a rare, life-threatening disease characterized by thrombocytopenia, microangiopathic hemolytic anemia, and acute renal failure. The atypical form of HUS (aHUS), representing 5 to 10% of cases, lacks the association with infection by Shiga toxin producing Escherichia coli strains that characterizes the commonest ...
Rodriguez de Cordoba, Santiago, Subias Hidalgo, Marta, Pinto, Sheila, Tortajada Alonso, Agustín   +3 more
openaire   +4 more sources

Atypical hemolytic uremic syndrome : update on the complement system and what is new [PDF]

, 2010
Atypical hemolytic uremic syndrome (aHUS) is a rare disease of microangiopathic hemolytic anemia, thrombocytopenia, and predominant renal impairment. It is characterized by the absence of Shiga toxin-producing bacteria as a triggering factor.
Dickenmann, Michael, Hirt-Minkowski, Patricia, Schifferli, Jürg A.   +2 more
core   +1 more source